WSTNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
WEST PHARMACEUTICAL SERVICES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026
$383.91−0.11 (-0.03%)
Close on Oct 19, 2026
- Market cap
- $27.37B
- P/E (TTM)
- 49.2
- Dividend yield
- 0.22%
WEST PHARMACEUTICAL SERVICES INC revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proprietary Products | $722.60M | $694.30M | $661.80M | $647.50M | $619.80M | $563.00M | $613.90M | $601.40M | $559.70M | $559.50M | $593.70M | $602.50M | 82.8% | +16.6% |
| West Vantage | $149.70M | $150.60M | – | – | $146.70M | $135.00M | – | – | – | – | – | – | 17.2% | +2.0% |
| Contract-Manufactured Products | – | – | – | – | – | – | – | – | – | – | – | $144.90M | – | – |
| Proprietary Products | – | – | – | – | – | – | – | – | – | – | – | $602.50M | – | – |
| Contract-Manufactured Products | – | – | $143.20M | $157.10M | $146.70M | $135.00M | $134.90M | $145.50M | $142.40M | $135.90M | $138.30M | $144.90M | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proprietary Products | $211.90M | $189.20M | $189.70M | $175.20M | $161.70M | $130.60M | $162.30M | $158.20M | $131.00M | $126.30M | $163.60M | $181.60M | +31.0% |
| West Vantage | $12.90M | $15.60M | – | – | $17.80M | $13.50M | – | – | – | – | – | – | -27.5% |
| Contract-Manufactured Products | – | – | – | – | – | – | – | – | – | – | – | $21.00M | – |
| Proprietary Products | – | – | – | – | – | – | – | – | – | – | – | $181.60M | – |
| Contract-Manufactured Products | – | – | $9.80M | $22.30M | $17.80M | $13.50M | $16.20M | $21.80M | $17.20M | $17.10M | $18.80M | $21.00M | – |
By product or service
By region
From the segment and revenue-disaggregation notes of West Pharmaceutical Services's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.